Westhampton Capital LLC Purchases 760 Shares of Johnson & Johnson $JNJ

Westhampton Capital LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.3% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 12,796 shares of the company’s stock after acquiring an additional 760 shares during the period. Johnson & Johnson makes up approximately 1.0% of Westhampton Capital LLC’s holdings, making the stock its 28th largest holding. Westhampton Capital LLC’s holdings in Johnson & Johnson were worth $1,955,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Highline Wealth Partners LLC boosted its position in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the 1st quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the 1st quarter valued at approximately $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $52,000. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Bank of America boosted their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Thursday, July 17th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Barclays boosted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Citigroup boosted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, August 21st. Finally, The Goldman Sachs Group boosted their price target on Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $181.40.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $185.99 on Thursday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $186.56. The firm has a market cap of $447.92 billion, a P/E ratio of 19.89, a PEG ratio of 2.36 and a beta of 0.40. The company has a 50 day moving average of $175.45 and a 200 day moving average of $162.51. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the business earned $2.82 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s payout ratio is currently 55.61%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.